Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

aTyr Pharma, Inc.

  • Sanjay Shukla, aTyr Pharma, Inc.

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. aTyr is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family. ATYR1923 is a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases.

  • Date:Monday, February 11
  • Time:9:30 AM - 9:45 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23506
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Investor Outreach and Updates
  • Company Website:www.atyrpharma.com
  • Company HQ City:San Diego
  • Company HQ State:California
  • Company HQ Country:United States
  • Ticker:LIFE
  • Exchange:NASDAQ
  • Main Therapeutic Focus:Immunology
  • Lead Product in Development:ATYR1923 for Pulmonary Sarcoidosis
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:aTyr is developing ATYR1923 as a potential therapeutic for patients with interstitial lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase (HARS) fused to the FC region of a human antibody, is a selective modulator of Neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr initiated a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis in the fourth quarter of 2018. This Phase 1b/2a study is a multiple-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and PK profile of multiple doses of ATYR1923. For the Phase 1b/2a trial, aTyr is collaborating with the Foundation for Sarcoidosis Research (FSR), the nation’s leading nonprofit organization dedicated to finding a cure for sarcoidosis and improving care for patients
Speakers
Sanjay Shukla
aTyr Pharma, Inc.
Back